Trial site
Syrentis Clinical Research
Santa Ana, California 92705, United StatesNot linked to an institution yet
- 15running trials
- 20closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 322 trials
- Phase 27 trials
- Phase 1/21 trial
- Status
- Completed14 trials
- Active, not recruiting10 trials
- Terminated6 trials
- Recruiting4 trials
- Enrolling by invitation1 trial
- Suspended1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- Eli Lilly and Company4 trials
- Hoffmann-La Roche3 trials
- Biogen2 trials
- Cassava Sciences, Inc.2 trials
- and 17 more
Running trials
Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· Phase 3· Eli Lilly and Company· Source
Contact: John Duffy (principal investigator)
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360· Phase 2· Weill Medical College of Cornell University· Source
Enrolling by invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031· Cognito Therapeutics, Inc.· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173· Phase 2· Acumen Pharmaceuticals· Source
Recruiting
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963· Phase 1/2· NKGen Biotech, Inc.· Source
Contact: Nikole Bo
Active, not recruiting
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301· Phase 2· University of Arizona· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940· Phase 3· COMPASS Pathways· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012· Phase 2· Janssen Research & Development, LLC· Source
Completed
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT06810050· Phase 2· CAGE Bio Inc.· Source
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· Phase 3· Janssen Research & Development, LLC· Source
Completed
Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS
NCT05996575· Kernel· Source
Completed
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
NCT05615220· Phase 3· Emalex Biosciences Inc.· Source
Completed
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
NCT05637801· Cognito Therapeutics, Inc.· Source
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076· Phase 3· Cassava Sciences, Inc.· Source
Completed
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
NCT05536414· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05455684· Phase 3· Janssen Research & Development, LLC· Source
Completed
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307· Global Alzheimer's Platform Foundation· Source
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· Phase 3· Biogen· Source
Completed
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT04994483· Phase 3· Cassava Sciences, Inc.· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· Phase 3· Novo Nordisk A/S· Source
Terminated
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
NCT04951284· Novoic Limited· Source
Completed
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
NCT04533529· Phase 3· Janssen Research & Development, LLC· Source
Terminated
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· Phase 3· Biogen· Source
Recruiting
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715· LivaNova· Source
Contact: Laura Yates, BSN
Completed
Memory Improvement Through Nicotine Dosing (MIND) Study
NCT02720445· Phase 2· University of Southern California· Source
Terminated
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Report an error